Literature DB >> 19921694

MicroRNA-34a is an important component of PRIMA-1-induced apoptotic network in human lung cancer cells.

Wenrui Duan1, Li Gao, Xin Wu, Li Wang, Serge P Nana-Sinkam, Gregory A Otterson, Miguel A Villalona-Calero.   

Abstract

Restoration of p53 function in tumor cells would be an attractive strategy for lung cancer therapy because p53 mutations are found in more than 50% of lung cancers. The small molecule PRIMA-1 has been shown to restore the tumor suppression function of p53 and to induce apoptosis in human tumor cells. The mechanism of apoptosis induced by PRIMA-1 remains unclear. We investigated the effects of PRIMA-1 in apoptosis with Western immunoblot analysis, TaqMan microRNA real-time PCR, cell viability analysis and flow cytometry using human lung cancer cell lines containing mutant (H211 and H1155), wild-type (A549) or null (H1299) p53. PRIMA-1 induced massive apoptosis in the H211 and H1155 cells, but was less toxic to the A549 and H1299 cells. Western immunoblot analysis showed cleavage of PARP in H211 and H1155 cells but not in A549 and H1299 cells following treatment with PRIMA-1. In addition, p53 protein was also phosphorylated in H211 and H1155 cells. TaqMan microRNA assay showed that the expression of microRNA-34a was increased in the H211 and H1155 cells posttreatment. Knockdown microRNA-34a decreased the rate of apoptosis caused by PRIMA-1. The above results suggest that microRNA-34a is one of the important components of PRIMA-1-induced apoptotic network in the cancer cells harboring mutant p53.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19921694      PMCID: PMC4153870          DOI: 10.1002/ijc.25049

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  33 in total

1.  Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription.

Authors:  Jerry E Chipuk; Ulrich Maurer; Douglas R Green; Martin Schuler
Journal:  Cancer Cell       Date:  2003-11       Impact factor: 31.743

Review 2.  p53: puzzle and paradigm.

Authors:  L J Ko; C Prives
Journal:  Genes Dev       Date:  1996-05-01       Impact factor: 11.361

Review 3.  p53, the cellular gatekeeper for growth and division.

Authors:  A J Levine
Journal:  Cell       Date:  1997-02-07       Impact factor: 41.582

4.  The IARC TP53 database: new online mutation analysis and recommendations to users.

Authors:  Magali Olivier; Ros Eeles; Monica Hollstein; Mohammed A Khan; Curtis C Harris; Pierre Hainaut
Journal:  Hum Mutat       Date:  2002-06       Impact factor: 4.878

5.  Selective induction of apoptosis in mutant p53 premalignant and malignant cancer cells by PRIMA-1 through the c-Jun-NH2-kinase pathway.

Authors:  Yin Li; Yuehua Mao; Paul W Brandt-Rauf; Ann C Williams; Robert L Fine
Journal:  Mol Cancer Ther       Date:  2005-06       Impact factor: 6.261

6.  Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound.

Authors:  Vladimir J N Bykov; Natalia Issaeva; Alexandre Shilov; Monica Hultcrantz; Elena Pugacheva; Peter Chumakov; Jan Bergman; Klas G Wiman; Galina Selivanova
Journal:  Nat Med       Date:  2002-03       Impact factor: 53.440

7.  Phosphorylation of p53 serine 15 increases interaction with CBP.

Authors:  P F Lambert; F Kashanchi; M F Radonovich; R Shiekhattar; J N Brady
Journal:  J Biol Chem       Date:  1998-12-04       Impact factor: 5.157

8.  DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2.

Authors:  S Y Shieh; M Ikeda; Y Taya; C Prives
Journal:  Cell       Date:  1997-10-31       Impact factor: 41.582

9.  Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations.

Authors:  Y Cho; S Gorina; P D Jeffrey; N P Pavletich
Journal:  Science       Date:  1994-07-15       Impact factor: 47.728

10.  p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features.

Authors:  T Mitsudomi; S M Steinberg; M M Nau; D Carbone; D D'Amico; S Bodner; H K Oie; R I Linnoila; J L Mulshine; J D Minna
Journal:  Oncogene       Date:  1992-01       Impact factor: 9.867

View more
  15 in total

Review 1.  Non-coding RNAs as theranostics in human cancers.

Authors:  Roxana S Redis; Ioana Berindan-Neagoe; Victor I Pop; George A Calin
Journal:  J Cell Biochem       Date:  2012-05       Impact factor: 4.429

Review 2.  Pharmacological activation of p53 in cancer cells.

Authors:  Mohammad Athar; Craig A Elmets; Levy Kopelovich
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

3.  Assessment of FANCD2 nuclear foci formation in paraffin-embedded tumors: a potential patient-enrichment strategy for treatment with DNA interstrand crosslinking agents.

Authors:  Wenrui Duan; Li Gao; Weiqiang Zhao; Marino Leon; Wolfgang Sadee; Amy Webb; Kimberly Resnick; Xin Wu; Bhuvaneswari Ramaswamy; David E Cohn; Charles Shapiro; Paul R Andreassen; Gregory A Otterson; Miguel A Villalona-Calero
Journal:  Transl Res       Date:  2012-10-11       Impact factor: 7.012

4.  MicroRNAs - Important Molecules in Lung Cancer Research.

Authors:  Petra Leidinger; Andreas Keller; Eckart Meese
Journal:  Front Genet       Date:  2012-01-23       Impact factor: 4.599

5.  Fanconi anemia repair pathway dysfunction, a potential therapeutic target in lung cancer.

Authors:  Wenrui Duan; Li Gao; Brittany Aguila; Arjun Kalvala; Gregory A Otterson; Miguel A Villalona-Calero
Journal:  Front Oncol       Date:  2014-12-19       Impact factor: 6.244

6.  Hypoxic resistance of KRAS mutant tumor cells to 3-Bromopyruvate is counteracted by Prima-1 and reversed by N-acetylcysteine.

Authors:  Andrea Orue; Valery Chavez; Mary Strasberg-Rieber; Manuel Rieber
Journal:  BMC Cancer       Date:  2016-11-18       Impact factor: 4.430

Review 7.  PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies.

Authors:  Anne Perdrix; Ahmad Najem; Sven Saussez; Ahmad Awada; Fabrice Journe; Ghanem Ghanem; Mohammad Krayem
Journal:  Cancers (Basel)       Date:  2017-12-16       Impact factor: 6.639

8.  miR-Explore: Predicting MicroRNA Precursors by Class Grouping and Secondary Structure Positional Alignment.

Authors:  Bram Sebastian; Samuel E Aggrey
Journal:  Bioinform Biol Insights       Date:  2013-04-02

9.  PA28gamma emerges as a novel functional target of tumour suppressor microRNA-7 in non-small-cell lung cancer.

Authors:  S Xiong; Y Zheng; P Jiang; R Liu; X Liu; J Qian; J Gu; L Chang; D Ge; Y Chu
Journal:  Br J Cancer       Date:  2013-11-26       Impact factor: 7.640

Review 10.  The role of microRNAs in the regulation of apoptosis in lung cancer and its application in cancer treatment.

Authors:  Norahayu Othman; Noor Hasima Nagoor
Journal:  Biomed Res Int       Date:  2014-06-05       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.